Merck & Co., Inc. vs SMX Security Matters plc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while SMX Security Matters plc trades at $3.79 (market cap $4.13M). The key difference: Merck & Co., Inc. is far larger — about 85055.7× SMX Security Matters plc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and SMX Security Matters plc for 21 Days on average.
| MRK | SMX | |
|---|---|---|
Market Cap | $351.28B | $4.13M |
Volume | 7,969,665 | 124,362 |
Sector | Health | Industrials |
52-Week High | $156.43 | $74.08K |
52-Week Low | $82.49 | $3.79 |
Typical Hold Time | 98 Days | 21 Days |
Enterprise Value | $398.04B | -$27.20M |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
SMX trades at $3.79, down 2.82% today, amid bearish technical signals from moving averages. The company reported no revenue in 2025, with a net loss of $169.18M and negative cash flow from operations, though financing activities provided a net cash inflow. Recent news highlights its Digital Material Passport platform and media coverage from outlets like Forbes and Boston Herald.
The outlook is highly speculative given the lack of revenue and deep losses. Investment hinges on future commercialization of its recycling technology. Key risks include execution challenges, cash burn, and competitive pressures. Analyst sentiment is not available, but institutional backing via financing offers some support amid fundamental weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →